Zoetis Inc. $ZTS Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 16.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 165,570 shares of the company’s stock after acquiring an additional 23,687 shares during the period. Pacer Advisors Inc.’s holdings in Zoetis were worth $19,572,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZTS. RFG Advisory LLC increased its position in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after buying an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. lifted its position in shares of Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. lifted its position in shares of Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its stake in shares of Zoetis by 20.9% during the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after acquiring an additional 90 shares during the last quarter. Finally, Physician Wealth Advisors Inc. increased its position in Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other news, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 11,650 shares of company stock valued at $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Zoetis Trading Down 0.2%

ZTS stock opened at $77.13 on Tuesday. The company has a market cap of $32.33 billion, a price-to-earnings ratio of 12.79, a PEG ratio of 1.21 and a beta of 0.73. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business has a fifty day simple moving average of $76.97 and a 200-day simple moving average of $101.99. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period last year, the business posted $1.48 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. TD Cowen lowered their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Citigroup cut their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, Barclays reduced their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average price target of $118.33.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.